Senior Israeli policymakers have been discussing the implications of proposals to revise the country's patent law. The proposals come from the Gabai Committee, which was set up in April 1995 following changes to US drug patent laws and as a result of pressure from drug firms, particularly Teva, on the Minister of Justice, David Libai, and the Industry and Commerce Minister.
Prof Libai asked a retired judge to give his opinion on the Committee's recommendations. It is understood that he approved them, and offered not only legal opinion but also considered their implications for the economy and industry. Because of their economic implications, US ambassador to Israel martin Indyk requested that the Embassy's opinion be passed to the judge. Some observers believe the proposals are risky, while others feel they would allow smaller companies to survive.
The change to US law enabled generic firms to start development work and preparation for registration before expiry, and also allowed the patent holder to extend the effective patent life. Israel's current law forbids any working of a valid patent, nor does it allow extension of the period over 20 years. The proposals would allow the patent to be worked prior to expiry.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze